The present invention provides an anti-androgen for treating metastatic castration-sensitive prostate cancer, which includes, but is not limited to 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.
This document is a Chinese invention patent application published on 2021-09-07 as CN 113365623 A. It was filed by Aragon Pharmaceuticals (阿拉和贡药品公司) on 2020-01-30 and claims priority to several US provisional applications; the PCT application was published as WO2020/157699.
The claims describe methods for treating metastatic castration-sensitive prostate cancer in male humans with anti-androgens, including apalutamide, alone or with androgen deprivation therapy. They also mention oral dosing ranges, combination with GnRH agonists/antagonists or bilateral orchiectomy, and restrictions on co-administration with certain drugs. This manual is written in Chinese.
It concerns methods for treating metastatic castration-sensitive prostate cancer in male humans.
The claims mention oral administration at about 240 mg per day.
Yes, the claims describe combination with androgen deprivation therapy.